Galectin-1 Macrophage Polarization for LGMD2B Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for limb-girdle muscular dystrophy 2B (LGMD2B) are ineffective, lacking targeted therapies and primarily focused on symptom management, with chronic inflammation and muscle degeneration being major contributors to the disease progression.
Innovation Solution
Administration of recombinant human galectin-1 (rHsGal-1) protein or its fragments, which polarizes resident macrophages to an M2 phenotype, reducing inflammation and enhancing muscle repair by increasing myogenic transcription factors and improving membrane repair capacity in dysferlin-deficient cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for LGMD2B are used, then symptom management is provided, but muscle degeneration and chronic inflammation are not effectively addressed
Solution Approach 1:
Galectin-1 acts as a mediator protein that modulates the immune response by polarizing macrophages from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype. This intermediary action reduces chronic inflammation and creates a favorable environment for muscle regeneration, directly addressing the harmful effects of current ineffective treatments
Solution Approach 2:
The treatment changes the phenotypic parameter of macrophages from M1 to M2 through galectin-1 administration. This parameter change in macrophage polarization shifts the immune response from proinflammatory to anti-inflammatory, thereby reducing muscle degeneration and improving treatment effectiveness for LGMD2B
2Strength
If dysferlin-deficient myoblasts are present, then muscle membrane repair is disrupted, but myogenesis is also decreased
Solution Approach 1:
The patent converts the harmful chronic inflammatory environment into a beneficial regenerative environment by using galectin-1 to polarize macrophages to M2 phenotype. This transforms the pathological condition into an opportunity for enhanced muscle regeneration and membrane repair, benefiting from the altered immune response
Solution Approach 2:
Galectin-1 treatment enables the muscle tissue to self-regenerate by improving both membrane repair capacity and myogenesis simultaneously. The anti-inflammatory M2 macrophages create an environment that supports endogenous muscle regeneration processes, allowing the tissue to repair itself without direct external intervention in the myogenic pathway
Data Source
AI summary
A method of treating a disease associated with chronic, NFκB canonical inflammation is disclosed herein. The method includes administering to a patient a suitable amount of a galectin-1 protein or fragment thereof. Treatment with a recombinant galectin-1 reduced inflammation in key inflammatory pathways.